Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Mar 4;26(4):515-523.
doi: 10.1093/ibd/izz193.

Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn's Disease

John George  1 , Siddharth Singh  2   3 , Parambir S Dulai  2 , Christopher Ma  4   5 , Tran Nguyen  4 , Brian G Feagan  4   6   7 , William J Sandborn  2 , Vipul Jairath  4   6   7
Affiliations
Meta-Analysis

Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn's Disease

John George et al. Inflamm Bowel Dis. .

Abstract

Background: We summarized the protocol-specified corticosteroid tapering regimens in clinical trials of moderate-severe ulcerative colitis (UC) and Crohn's disease (CD) and calculated differences in rates of clinical remission vs corticosteroid-free clinical remission (CSF-CR).

Methods: Through a systematic literature review through February 28, 2019, we identified 16 randomized controlled trials (RCTs) of biologics or small molecules in patients with moderate-severe UC or CD who reported CSF-CR as an outcome. We estimated the relative risk and 95% confidence interval of achieving CSF-CR vs overall clinical remission in patients treated with active intervention or placebo through random-effects meta-analysis.

Results: Across trials of UC (11 trials) and CD (5 trials), a median of 53% and 49% of participants were on corticosteroids at the time of trial entry, respectively. Participants were allowed to enter trials at a median corticosteroid dose (range) of 35 (20-40) mg/d. Doses were kept stable for a median (range) of 8 (5-10) weeks during induction therapy, after which a mandatory and structured taper was implemented, albeit with the investigators' discretion depending on clinical status. Pooled rates of CSF-CR in patients with UC and CD treated with placebo were 9.7% and 19.1%, respectively. In UC and CD trials, the rate of CSF-CR was 24% and 18% lower than the rate of overall clinical remission, respectively.

Conclusions: Protocol-specified corticosteroid tapering regimens vary across trials. These findings will help to inform the design and interpretation of future clinical trials and highlight the need for standardization.

Keywords: Crohn’s disease; clinical trials; end points; maintenance therapy; ulcerative colitis.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
Study selection flowsheet.
FIGURE 2.
FIGURE 2.
Risk of achieving corticosteroid-free remission vs overall clinical remission in patients with moderate to severe ulcerative colitis.
FIGURE 3.
FIGURE 3.
Risk of achieving corticosteroid-free remission vs overall clinical remission in patients with moderate to severe Crohn’s disease.
See this image and copyright information in PMC

References

    1. Huscher D, Thiele K, Gromnica-Ihle E, et al. . Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68:1119–1124. - PubMed
    1. Ma C, Hussein IM, Al-Abbar YJ, et al. . Heterogeneity in definitions of efficacy and safety endpoints for clinical trials of Crohn’s disease: a systematic review. Clin Gastroenterol Hepatol. 2018;16:1407–1419.e22. - PubMed
    1. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group . Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9, W64. - PubMed
    1. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188. - PubMed
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560. - PMC - PubMed

MeSH terms

Substances